Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 10/20 | 0.96 |
| ▸ | ADRA2C known ✓ | P18825 | 9/20 | 0.96 |
| ▸ | ADRA1D known ✓ | P25100 | 6/20 | 0.96 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.96 |
| ▸ | ADRA1B known ✓ | P35368 | 6/20 | 0.96 |
| ▸ | ADRA2B known ✓ | P18089 | 3/20 | 0.47 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.47 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.45 |
| ▸ | HRH2 known ✓ | P25021 | 1/20 | 0.45 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.45 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.37 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.37 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.36 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13767327 | 0.98 | ADRA2A (1.00) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| Hydrochloric Acid SCHEMBL11125153 | 0.79 | ADRA2A (0.62) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL11096814 | 0.77 | ADRA2A (0.64) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL17459143 | 0.76 | ADRA2A (0.62) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL1845396 | 0.75 | ADRA2A (0.62) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL708660 | 0.72 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL11095405 | 0.72 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL6054541 | 0.72 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL16180456 | 0.71 | ADRA2A (0.57) | ADRA2AADRA2CADRA1DADRA1AADRA1B | |
| SCHEMBL17713794 | 0.71 | ADRA2A (0.56) | ADRA2AADRA2CADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3004138-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Synergy Pharmaceuticals Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014197720-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | SYNERGY PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2009129387-A2 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| EP-1857445-B1 | Substituted 2 amino imidazoles, method for their manufacture and their use as a drug or diagnostic and drug containing them | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-20080275098-A1 | Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-11-06 | — | — | US | disclosed |
| US-7442717-B2 | Substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| EP-1857445-A2 | Substituted 2 amino imidazoles, method for their manufacture and their use as a drug or diagnostic and drug containing them | Sanofi-Aventis Deutschland GmbH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1592669-B1 | SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1592669-A2 | NOVEL SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-09 | — | — | EP | disclosed |
| US-20040259927-A1 | Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-23 | — | — | US | disclosed |
| WO-2004069806-A2 | SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259927-A1 | Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | NDUFAB1, ABAT, NDUFAF1 | ADRA2A 701/4885ADRA2C 620/4885ADRA1D 443/4885 |
| US-20080275098-A1 | Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents | ATP6V1B1, SLC10A1, GLS | ADRA2A 548/4885ADRA2C 354/4885ADRA1D 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.